Back to companies

Oxford BioMedica Plc (Oxford Biomedica) is a biopharmaceutical company involved in the development and commercialization of gene-based medicines. It has LentiVector, a sector leading lentiviral vector delivery platform. Based on this platform the company has developed a portfolio of gene and cell therapy product candidates in ophthalmology, oncology, central nervous system (CNS), and other therapy areas. It has partnership and license agreement with other companies to develop potential gene and cell therapy products. The company has presence in different locations in Oxfordshire, the UK. Oxford BioMedica is headquartered in Oxford, the UK.

Headquarters United Kingdom

Address Windrush Court, Transport Way, Oxford, OX46LT


Telephone 44 1865 783000

No of Employees 815

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange OXB (LON)

Revenue (2020) $196.4M 62.8% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX 404.4% (2020 vs 2019)

Market Cap* $374.0M

Net Profit Margin (2020) XXX 286.9% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for Oxford BioMedica Plc

30+

Pipeline Drugs

Identify which of Oxford BioMedica Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Clinical Trials

Determine Oxford BioMedica Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

15+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Oxford BioMedica Plc’s relevant decision makers and contact details.

20+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Oxford BioMedica Plc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services Brands
Approved: CDMO Kymriah
Kymriah- Relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL)
Pipeline
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In September, the company entered into an agreement with an undisclosed the US-based late-stage cell and gene therapy company to utilise Oxford Biomedica's LentiVector platform for its application in their lead programme.
2022 Contracts/Agreements In September, Oxford Biomedica Solutions LLC signed an agreement with an undisclosed US-based private biotechnology company to provide The Full Solution from construct design to process development to IND support.
2022 Contracts/Agreements In July, the company signed a licence & supply agreement with New Partner for LentiVector platform for CAR-T therapy.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Oxford BioMedica Plc Almac Group Ltd Agenus Inc Alliance Pharma Plc Transgene SA
Headquarters United Kingdom United Kingdom United States of America United Kingdom France
City Oxford Craigavon Lexington Chippenham Illkirch-Graffenstaden
State/Province - Northern Ireland Massachusetts - -
No. of Employees 815 5,783 441 255 165
Entity Type Public Private Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Stuart Paynter Chief Financial Officer; Director Executive Board 2017 -
Nick Page Chief Operating Officer Senior Management 2019 -
Matthew Treagus Chief Information Officer Senior Management 2021 -
Helen Stephenson-Ellis Chief People Officer Senior Management 2018 -
Kyriacos Mitrophanous Chief Scientific Officer Senior Management 2014 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer